Life sciences - Pharmacovigilance
10 October 2019
Over the years pharmacovigilance has always been an important aspect of drug development, and has often been neglected by pharma and biotech companies when forecasting drug development costs. The market includes companies ranging from small “one man bands”, all the way up to global CROs. Larger CROs leverage their presence in other drug development services to cross-sell PV services while smaller firms focus more on bespoke regulatory strategy and consultancy. This is a fast growing area of Life Sciences and provides huge opportunities for investors and buyers.
As you will discover in the our analysis, the main themes of the sector are further outsourcing and consolidation. Smaller firms are merging to achieve scale and additional geographical coverage, while larger firms are aiming to broaden expertise and capability across bespoke strategic services. There are lots of opportunities to invest in PV companies as they aim to grow either organically or through acquisitions.
The BDO Life Sciences team has vast experience and interest in the field of outsourced pharma solutions. We work with businesses at every stage of the business life-cycle and understand the challenges and opportunities they face. We also have Growth Advisory and Private Equity teams who can help bridge the gap between the investor and the business. We have drawn on publicly available sources, as well as conversations with industry leaders and key opinion leaders, to produce this report.
If you have any questions please contact Anand Ashok.
This document is best viewed in Adobe Acrobat Reader